PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis

Antiangiogenic therapy is a recognized method for countering the immunosuppressive tumor microenvironment (TME) and improving anti-tumor immunity. PB101 is a glycosylated decoy receptor that binds to VEGF-A and PlGF with high affinity, based on the VEGFR1 backbone. Here, we elucidated PB101-induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Go, Eun-Jin, Yang, Hannah, Lee, Seung Joon, Yang, Hyun Gul, Shin, Jin A., Lee, Won Suk, Lim, Hye Seong, Chon, Hong Jae, Kim, Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515676/
https://www.ncbi.nlm.nih.gov/pubmed/37744990
http://dx.doi.org/10.1080/2162402X.2023.2259212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515676/
https://www.ncbi.nlm.nih.gov/pubmed/37744990
http://dx.doi.org/10.1080/2162402X.2023.2259212

Ejemplares similares